Literature DB >> 17010577

LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance.

Miroslav Barancík1, Vierka Bohácová, Ján Sedlák, Zdenka Sulová, Albert Breier.   

Abstract

The transmembrane transport pump P-glycoprotein (P-gp) causes the efflux of chemotherapeutic agents from cells and is an important system that secures multidrug resistance (MDR) of neoplastic cells. In the present study drug sensitive L1210 and multidrug resistant L1210/VCR mouse leukemic cell lines were used as an experimental model. We found that LY 294,002, a specific inhibitor of PI3K/Akt kinase pathway, reduced the degree of vincristine resistance in L1210/VCR cells significantly and in a concentration-dependent manner. This was accompanied by decrease in IC(50) value to vincristine from 3.195+/-0.447 to 1.898+/-0.676 micromol/l for 2 micromol/l, to 0.947+/-0.419 micromol/l for 4 micromol/l, and to 0.478+/-0.202 micromol/l for 8 micromol/l LY294,002. The IC(50) value of sensitive cells for vincristine was about 0.010 micromol/l. FACS analysis of the proportion of cells in apoptosis or necrosis by annexin-V apoptosis kit showed the following: (i) vincristine-induced apoptosis in resistant cell to a much lower extent than in sensitive cells; (ii) LY294,002 alone did not induce apoptosis or necrosis in both sensitive and resistant cells; (iii) LY294,002 applied together with vincristine significantly increased the number of apoptotic cells. Transport activity of P-gp in resistant cells was monitored using calcein/AM as substrate and was depressed by LY294,002 in a concentration dependent manner. Significant differences in calcein retention were not observed when cells were preincubated with LY294,002 at different times from 0.5 to 24h. Sensitive and resistant cells contain similar amounts of uncleaved (i.e., unactivated) caspase-3 but in latter cells the activation of caspase-3 by proteolytic cleavage was decreased. The reversal of vincristine resistance by LY294,002 was associated with marked activation of caspase-3. Western blot analysis revealed that the development of MDR phenotype in L1210/VCR cells was also associated with increased level of Bcl-2 protein. All the above findings point to the possible involvement of PI3K/Akt kinase pathway in modulation of P-gp mediated multidrug resistance in L1210/VCR mouse leukemic cell line. MDR reversal effect of LY294,002 is accompanied with this compound's influence on vincristine-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010577     DOI: 10.1016/j.ejps.2006.08.006

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  25 in total

Review 1.  ABC transporters as molecular effectors of pancreatic oncogenic pathways: the Hedgehog-GLI model.

Authors:  Marta Santisteban
Journal:  J Gastrointest Cancer       Date:  2010-09

2.  CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.

Authors:  G Xi; E Hayes; R Lewis; S Ichi; B Mania-Farnell; K Shim; T Takao; E Allender; C S Mayanil; T Tomita
Journal:  Oncogene       Date:  2015-03-30       Impact factor: 9.867

3.  Inhibition of the PI3K/AKT Pathway Sensitizes Oral Squamous Cell Carcinoma Cells to Anthracycline-Based Chemotherapy In Vitro.

Authors:  Dmitriy Smolensky; Kusum Rathore; Jennifer Bourn; Maria Cekanova
Journal:  J Cell Biochem       Date:  2017-05-16       Impact factor: 4.429

4.  PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma.

Authors:  Feifei Wen; Shuang He; Chenbo Sun; Tangyue Li; Shuhua Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 5.  Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities.

Authors:  Macus Tien Kuo
Journal:  Antioxid Redox Signal       Date:  2009-01       Impact factor: 8.401

6.  PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma.

Authors:  Shuhua Wu; Feifei Wen; Yangyang Li; Xiangqian Gao; Shuang He; Mengyao Liu; Xiangzhi Zhang; Dong Tian
Journal:  Tumour Biol       Date:  2016-01-08

7.  Cholecalciferol-PEG Conjugate Based Nanomicelles of Doxorubicin for Treatment of Triple-Negative Breast Cancer.

Authors:  Shallu Kutlehria; Gautam Behl; Ketan Patel; Ravi Doddapaneni; Imran Vhora; Nusrat Chowdhury; Arvind Bagde; Mandip Singh
Journal:  AAPS PharmSciTech       Date:  2017-10-10       Impact factor: 3.246

8.  The role of E3 ubiquitin ligase Cbl proteins in β-elemene reversing multi-drug resistance of human gastric adenocarcinoma cells.

Authors:  Ye Zhang; Xiao-Dong Mu; En-Zhe Li; Ying Luo; Na Song; Xiu-Juan Qu; Xue-Jun Hu; Yun-Peng Liu
Journal:  Int J Mol Sci       Date:  2013-05-10       Impact factor: 5.923

9.  Versatile inhibitory effects of the flavonoid-derived PI3K/Akt inhibitor, LY294002, on ATP-binding cassette transporters that characterize stem cells.

Authors:  Yasuo Imai; Hidetsugu Yamagishi; Yuko Ono; Yoshihiko Ueda
Journal:  Clin Transl Med       Date:  2012-10-13

10.  13-methyltetradecanoic acid exhibits anti-tumor activity on T-cell lymphomas in vitro and in vivo by down-regulating p-AKT and activating caspase-3.

Authors:  Qingqing Cai; Huiqiang Huang; Dong Qian; Kailin Chen; Junhua Luo; Ying Tian; Tianxin Lin; Tongyu Lin
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.